The obstructive airway diseases medicine sales in Canada are projected to climb steadily from 2024 to 2028, starting at $1.63 billion and reaching $1.71 billion. In 2023, actual sales stood at $1.61 billion. The annual growth rate averages at 1.2% over the forecast period, indicating a robust market expansion driven by rising incidence of respiratory conditions and advancing therapeutic options.
Future trends to watch include increased adoption of digital health technologies for remote management of chronic airway diseases, and potential market disruptions from emerging therapies and biosimilars, which could drive more cost-effective treatment options.
